IGFBP3 and hepatocellular carcinoma: TCGA analysis demonstrated that IGFBP3 upregulation dramatically impacted HCC patient survival outcomes including the overall survival (OS) rate and tumor‐free survival rate (DFS) (Figure 4H,I).